CEO Ryan Confer is scheduled to lead the presentation on Monday, September 14, at 3:30 p.m. ET at the Lotte New York Palace Hotel. His address will focus on Reqorsa Gene Therapy, the company’s lead candidate currently undergoing evaluation in the Acclaim-1 and Acclaim-3 clinical trials for lung cancer. The FDA has already granted Fast Track Designation to both programs, with Orphan Drug status assigned to the small cell lung cancer trial.
In section Releases
Genprex to Showcase Gene Therapy Pipeline at H.C. Wainwright Conference
Austin-based biotechnology firm Genprex will present its latest clinical and preclinical progress at the H.C. Wainwright 28th Annual Global Investment Conference in New York City. The company plans to outline the development trajectory for its oncology and diabetes programs during the three-day event held September 14–16.
Beyond oncology, the company will share updates on its diabetes research, which seeks to restore insulin-producing functions through cell reprogramming. Confer will be joined by Chief Medical Officer Dr. Mark Berger and Senior Vice President of Intellectual Property Thomas Gallagher, both of whom are slated to participate in one-on-one sessions with investors throughout the conference.
Comments (0)
No comments yet. Be the first!